Event Type
Disclosure
Mandatory
Variant
8-K
Completion of Acquisition or Disposition of Assets. On January 23, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) completed the previously announced acquisit
, including Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities under, Section 18 of the Securities
Other Events. Immediately following the consummation of the Mergers, the Company closed the two private placement offerings (the “Private Placements”) pursuant
(b) of Form 8-K by an amendment to this Form 8-K no later than 71 calendar days after the date this Form 8-K is required to be filed. (d) Exhibits. Exhibit No.